CY1121663T1 - Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate - Google Patents

Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate

Info

Publication number
CY1121663T1
CY1121663T1 CY20191100503T CY191100503T CY1121663T1 CY 1121663 T1 CY1121663 T1 CY 1121663T1 CY 20191100503 T CY20191100503 T CY 20191100503T CY 191100503 T CY191100503 T CY 191100503T CY 1121663 T1 CY1121663 T1 CY 1121663T1
Authority
CY
Cyprus
Prior art keywords
mixture
alaninyl
benzyloxy
phenyl
phosphate
Prior art date
Application number
CY20191100503T
Other languages
English (en)
Inventor
Christopher Mcguigan
Fabrizio PERTUSATI
Original Assignee
University College Cardiff Consultants Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121663(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en
Priority claimed from GB201307314A external-priority patent/GB201307314D0/en
Application filed by University College Cardiff Consultants Limited filed Critical University College Cardiff Consultants Limited
Publication of CY1121663T1 publication Critical patent/CY1121663T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S5/00—Semiconductor lasers
    • H01S5/30—Structure or shape of the active region; Materials used for the active region
    • H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
    • H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
    • H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η αποκάλυψη αφορά το Gemcitabine-[phenyl-(benzyloxy-L-alaninyl)] -phosphate με την μορφή ενός 20:1 Rp/Sp μίγματος και φαρμακευτικές συνθέσεις αυτού. Το παρόν μίγμα είναι χρήσιμο στη θεραπεία συμπαγούς καρκίνου, όπως του καρκίνου του στήθους, του ορθού και του προστάτη.
CY20191100503T 2012-11-16 2019-05-09 Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate CY1121663T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1220666.0A GB201220666D0 (en) 2012-11-16 2012-11-16 Process for preparing chemical compounds
GB201307314A GB201307314D0 (en) 2013-04-23 2013-04-23 Process for preparing chemical compounds
EP13792965.9A EP2920192B1 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
PCT/GB2013/053018 WO2014076490A1 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
EP16195036.5A EP3150616B1 (en) 2012-11-16 2013-11-15 Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate

Publications (1)

Publication Number Publication Date
CY1121663T1 true CY1121663T1 (el) 2020-07-31

Family

ID=49622844

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100539T CY1119161T1 (el) 2012-11-16 2017-05-24 Μιγμα rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
CY20191100503T CY1121663T1 (el) 2012-11-16 2019-05-09 Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100539T CY1119161T1 (el) 2012-11-16 2017-05-24 Μιγμα rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate

Country Status (28)

Country Link
US (3) US10005810B2 (el)
EP (3) EP3235824B1 (el)
JP (5) JP2016506371A (el)
KR (1) KR20150103669A (el)
CN (2) CN104903339A (el)
AU (1) AU2013346515B2 (el)
CA (1) CA2891266C (el)
CL (1) CL2015001307A1 (el)
CY (2) CY1119161T1 (el)
DK (2) DK3235824T3 (el)
EA (1) EA028871B1 (el)
ES (3) ES2725491T3 (el)
HR (2) HRP20170791T1 (el)
HU (2) HUE033335T2 (el)
IL (1) IL238792A (el)
IN (1) IN2015DN04090A (el)
LT (2) LT3150616T (el)
MX (1) MX374779B (el)
MY (1) MY176133A (el)
NZ (1) NZ708177A (el)
PH (1) PH12015501090B1 (el)
PL (2) PL3235824T3 (el)
PT (2) PT3235824T (el)
RS (2) RS58849B1 (el)
SG (3) SG10201510324YA (el)
SI (2) SI3235824T1 (el)
SM (2) SMT201700349T1 (el)
WO (1) WO2014076490A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
PT3235824T (pt) * 2012-11-16 2019-05-30 NuCana plc Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
MX2016006919A (es) * 2013-11-27 2016-08-17 Idenix Pharmaceuticals Llc Nucleotidos para el tratamiento de cancer de higado.
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
EP3757112B1 (en) * 2014-06-25 2023-06-07 Nucana PLC Gemcitabine prodrugs
AU2015278900B2 (en) 2014-06-25 2019-04-04 NuCana plc Formulation comprising a gemcitabine-prodrug
CN105254694B (zh) * 2014-07-14 2018-11-27 正大天晴药业集团股份有限公司 氘代核苷衍生物
EP3172218B1 (en) 2014-07-22 2020-10-21 NuCana plc Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
BR112017001847A2 (pt) * 2014-07-31 2018-02-27 Sandoz Ag processo para a preparação de um composto de fórmula (i), mistura, composição e composto de fórmula (ii)
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN105461774B (zh) * 2014-09-30 2020-11-24 江苏豪森药业集团有限公司 索非布韦的制备方法
CN105461773B (zh) * 2014-09-30 2020-12-01 江苏豪森药业集团有限公司 索非布韦的制备方法及其中间体
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
AU2016229966B2 (en) * 2015-03-06 2018-09-27 Atea Pharmaceuticals, Inc. Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10407456B2 (en) 2015-03-26 2019-09-10 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) * 2015-07-28 2021-05-11 广东东阳光药业有限公司 一种改良的索菲布韦制备方法
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106478753A (zh) * 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
WO2017060661A1 (en) * 2015-10-05 2017-04-13 Nucana Biomed Limited Combination therapy
WO2017090264A1 (ja) * 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
HRP20211812T1 (hr) * 2015-12-11 2022-03-04 NuCana plc Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) * 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
CN107652342A (zh) * 2016-07-23 2018-02-02 江苏万高药业股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
ES2907874T3 (es) 2016-09-07 2022-04-26 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-sustituidos-N6-sustituidos para el tratamiento de virus de ARN
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CA3041423A1 (en) * 2016-12-23 2018-06-28 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nucleoside phosphate compound and preparation method and use thereof
JP7066728B2 (ja) 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
CN111989335B (zh) 2018-06-12 2023-06-13 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
RU2740058C1 (ru) * 2020-06-26 2020-12-31 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用
WO2024107859A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
JP2002500880A (ja) 1998-01-23 2002-01-15 ニューバイオティックス インコーポレイテッド 酵素に触媒される治療剤
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
JP2005522443A (ja) 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
AU2003291726A1 (en) 2002-11-04 2004-06-07 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2007020193A2 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
BRPI1004575A2 (pt) * 2009-01-09 2016-04-05 Inhibitex Inc composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
UY33310A (es) * 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
US9090642B2 (en) * 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SG188497A1 (en) * 2010-09-22 2013-05-31 Alios Biopharma Inc Substituted nucleotide analogs
US8772474B2 (en) * 2010-12-22 2014-07-08 Alios Biopharma, Inc. Cyclic nucleotide analogs
MX339822B (es) * 2011-03-01 2016-06-13 Nucana Biomed Ltd Derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento contra el cancer.
BR112013022391A2 (pt) * 2011-03-02 2018-01-16 SCHENTAG Jerome composições, métodos de tratamento e diagnóstico para o tratamento de esteatose hepática apenas ou em combinação com uma infecção pelo vírus da hepatite c e uso dessas composições
KR20140103914A (ko) * 2011-10-14 2014-08-27 에스티씨. 유엔엠 운반물 경피 전달을 포함하는 타켓 전달용 다공성 나노입자-지지 지질 이중층(프로토셀) 및 그 방법
PT3235824T (pt) * 2012-11-16 2019-05-30 NuCana plc Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato
HK1224229A1 (zh) * 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷，核苷酸及其类似物
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
KR102314960B1 (ko) * 2013-10-11 2021-10-19 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체
MX2016006919A (es) 2013-11-27 2016-08-17 Idenix Pharmaceuticals Llc Nucleotidos para el tratamiento de cancer de higado.
JP2016538306A (ja) * 2013-11-27 2016-12-08 アメリカ合衆国 複素環化合物及びその使用方法
EP3757112B1 (en) 2014-06-25 2023-06-07 Nucana PLC Gemcitabine prodrugs
AU2015278900B2 (en) 2014-06-25 2019-04-04 NuCana plc Formulation comprising a gemcitabine-prodrug
EP3172218B1 (en) 2014-07-22 2020-10-21 NuCana plc Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
WO2016181093A1 (en) 2015-05-14 2016-11-17 Nucana Biomed Limited Cancer treatments
WO2017060661A1 (en) 2015-10-05 2017-04-13 Nucana Biomed Limited Combination therapy
HRP20211812T1 (hr) 2015-12-11 2022-03-04 NuCana plc Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
DK3393478T3 (da) 2015-12-23 2020-03-23 NuCana plc Kombinationsterapi
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
CA3008769A1 (en) 2015-12-23 2017-06-29 NuCana plc Combination therapy comprising nuc-1031 and cisplatin
GB201713914D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy
JP2020171815A (ja) * 2020-07-29 2020-10-22 株式会社ユニバーサルエンターテインメント プログラム

Also Published As

Publication number Publication date
LT3235824T (lt) 2019-07-10
EP3235824B1 (en) 2019-03-27
HK1210784A1 (en) 2016-05-06
AU2013346515A1 (en) 2015-06-04
JP7519259B2 (ja) 2024-07-19
PH12015501090A1 (en) 2015-07-27
KR20150103669A (ko) 2015-09-11
HRP20190831T1 (hr) 2019-08-23
US20180273575A1 (en) 2018-09-27
CN111592577A (zh) 2020-08-28
US20150291650A1 (en) 2015-10-15
JP2019196360A (ja) 2019-11-14
LT3150616T (lt) 2017-07-25
CA2891266A1 (en) 2014-05-22
ES2618732T3 (es) 2017-06-22
EA201590955A1 (ru) 2015-08-31
MY176133A (en) 2020-07-24
PL3235824T3 (pl) 2019-09-30
PH12015501090B1 (en) 2019-01-30
ES2725491T3 (es) 2019-09-24
JP2023052536A (ja) 2023-04-11
JP2021020919A (ja) 2021-02-18
SI3150616T1 (sl) 2017-08-31
PT3150616T (pt) 2017-06-09
JP2018009000A (ja) 2018-01-18
PT3235824T (pt) 2019-05-30
SMT201700349T1 (it) 2017-09-07
JP2016506371A (ja) 2016-03-03
US11040997B2 (en) 2021-06-22
US20220033433A1 (en) 2022-02-03
CY1119161T1 (el) 2018-02-14
EP2920192A1 (en) 2015-09-23
HUE044605T2 (hu) 2019-11-28
HRP20170791T1 (hr) 2017-08-25
IL238792A0 (en) 2015-06-30
PL3150616T3 (pl) 2017-09-29
CN104903339A (zh) 2015-09-09
HUE033335T2 (en) 2017-11-28
EA028871B1 (ru) 2018-01-31
CL2015001307A1 (es) 2015-12-11
RS56038B1 (sr) 2017-09-29
EP3235824A1 (en) 2017-10-25
SG10201510324YA (en) 2016-01-28
MX2015006195A (es) 2015-12-08
DK3235824T3 (da) 2019-05-20
US10005810B2 (en) 2018-06-26
SG11201503750YA (en) 2015-06-29
IN2015DN04090A (el) 2015-10-09
ES2627195T3 (es) 2017-07-27
WO2014076490A1 (en) 2014-05-22
NZ708177A (en) 2017-08-25
EP3150616B1 (en) 2017-05-10
MX374779B (es) 2025-03-06
CA2891266C (en) 2020-12-08
EP2920192B1 (en) 2017-02-22
SMT201900341T1 (it) 2019-07-11
SG10201510322UA (en) 2016-01-28
EP3150616A1 (en) 2017-04-05
BR112015011155A2 (pt) 2017-07-11
AU2013346515B2 (en) 2017-05-25
IL238792A (en) 2017-09-28
SI3235824T1 (sl) 2019-08-30
RS58849B1 (sr) 2019-07-31
DK3150616T3 (en) 2017-06-06

Similar Documents

Publication Publication Date Title
CY1121663T1 (el) Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1121546T1 (el) Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1121120T1 (el) Αρυλ- ή ετεροαρυλ-υποκατεστημενες ενωσεις βενζολιου
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
BR112014031421A2 (pt) composições para tratamento de câncer e métodos para produção das mesmas
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
CY1121450T1 (el) Θεραπεια συνδυασμου για θεραπεια καρκινου
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CY1117956T1 (el) N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα
BR112015019432A2 (pt) Compostos de tubulisina, métodos de produção e uso
MX2016007585A (es) Inhibidores de desmetilasa-1 especifica de lisina.
EA201290901A1 (ru) Фитоканнабиноиды для лечения злокачественной опухоли
MX2021002713A (es) Modulador del receptor de androgeno y usos de este.
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
EA201291194A1 (ru) Индолы
NI201500088A (es) Inhibidores de histona desmetilasa
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX2016004678A (es) Composiciones para el tratamiento del cancer.
EA201592093A1 (ru) Композиции и способы модулирования экспрессии hbv и ttr
MX2017000168A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX377405B (es) Compuestos para el tratamiento de cáncer.